Philips Wins FDA Clearance for AI DeviceGuide in Mitral Valve Repair
Philips received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered software that tracks and visualizes the Edwards PASCAL Ace mitral valve repair device in real time during minimally invasive M-TEER procedures. The solution integrates with the Azurion platform to streamline cardiology workflows and support clinician precision.
1. FDA Clearance for EchoNavigator R5.0 with DeviceGuide
Philips received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, marking the first AI-powered navigation software approved for mitral transcatheter edge-to-edge repair procedures. Developed in collaboration with Edwards Lifesciences, the solution aims to assist clinicians in one of interventional cardiology’s most complex workflows by providing real-time guidance during mitral valve repair.
2. AI-Powered Navigation and Workflow Integration
DeviceGuide integrates live ultrasound from the EPIQ CVxi cardiovascular platform with X-ray imaging on the Azurion system to provide a unified view of the Edwards PASCAL Ace repair device. The AI algorithm automatically tracks device orientation and trajectory in real time, offering physicians visual overlays, trajectory lines, and orientation cues to improve procedural accuracy and team coordination.
3. Market Impact and Strategic Positioning
Mitral regurgitation affects over 35 million adults worldwide and drives growing demand for transcatheter repair techniques as an alternative to open heart surgery. The FDA clearance positions Philips to expand its connected cardiology portfolio, potentially boosting Azurion installations, strengthening its strategic partnership with Edwards Lifesciences, and enhancing its competitive edge in structural heart therapy solutions.